Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, shows significant benefit among patients with EGFR T790M mutation at disease progression. We analyzed the whole exome sequence of 48 samples obtained from 16 lung cancer patients with a longitudinal follow-up: treatment-naïve-baseline p...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Asim Joshi, Ashwin Butle, Supriya Hait, Rohit Mishra, Vaishakhi Trivedi, Rahul Thorat, Anuradha Choughule, Vanita Noronha, Kumar Prabhash, Amit Dutt
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	Elsevier 2022-08-01
श्रृंखला:	Translational Oncology
विषय:	Erlotinib resistance Low allele fraction EGFR T790M Osimertinib Orthotopic lung cancer mice model Bioluminescence imaging Next generation sequencing
ऑनलाइन पहुंच:	http://www.sciencedirect.com/science/article/pii/S1936523322001206
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!